An interventional study of Chatbot in Breast Cancer, sponsored by University of Utah. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by University of Utah · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Breast Neoplasms by University of Utah — 9 open to participants now, 9 under way, 1 of them phase 3. Breast Neoplasms · University of Utah.
Among the 33 studies in Breast Neoplasms by University of Utah, this one has the largest planned enrollment, is one of 8 that started in 2025, is one of 14 with no phase, and was the 27th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 33 studies in Breast Neoplasms by University of Utah are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+ · Women only
University of Utah · Sites in United States
Ages 18+ · Women only
University of Utah · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 2 · Phase 4 1
First in 2006; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,700 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 34 across the 33 interventional studies. Of the 22 that completed or were terminated, 6 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
6 of the studies in Breast Neoplasms by University of Utah that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07166042Phase 3University of UtahGuided Meditation During Radiation Therapy for Breast and Gynecological Malignancies | 2027-11 |
| NCT05464082University of UtahFunctional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC | 2026-12-30 |
| NCT05291507University of UtahFeasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System | 2027-01 |
| NCT07044583University of UtahSAVE Trial: SAfe Opioid Use Video Education | 2027-08 |
| NCT07120100University of UtahTranscranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors | 2027-09-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 33 studies in Breast Neoplasms by University of Utah, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is investigating the feasibility of a digital tool called a chatbot for providing educational information about mammography through a tablet, computer, or phone. This study will recruit participants who recently had a mammogram with the University of Utah. Based on their mammography results, women will be placed into two cohorts using their BI-RADS category. Once mammogram results are available, patients will be randomized 1:1 to either usual care or usual care with chatbot. This study will randomly invite participants from four groups for focus group discussions (FGDs) based on their mammogram results and adherence to screening recommendations
Breast cancer screening inequities are drivers of disparities for rural and Latina women.
Chatbots are increasingly popular in various healthcare contexts and can be easily accessed through smartphones, tablets, laptops, and desktops. Chatbots have many advantages for patient messaging, including providing scripted education and motivational information interactively, chunking information into digestible segments, and allowing for choice in the amount of information received at any one time. Thus, with chatbots this study can tailor the interaction based on individual patient factors. Chatbots are accessible to the vast majority of U.S. adults. While chatbots have been used successfully in some clinical contexts, there is a lack of studies that investigated the use of chatbots as part of a mobile screening program to increase adherence to follow-up recommendations about either screening or diagnostic care.
Study staff will approach women at the time of or soon after a patient's routine breast cancer screening and invite the patient to participate in the study. Participants will complete baseline surveys at time of enrollment. This survey includes demographics and preferred contact method (e.g., text, email) that will be used to initiate the chatbot communication which can be completed via phone or website. Usual clinical procedures will be used to interpret participants' routine screening mammograms, including the use of the breast imaging-reporting and data system (BI-RADS), typically within 1 week of imaging.
Based on their mammography results, women will be placed into two cohorts using their BI-RADS category.
All participants will complete follow-up questionnaires, available in English and Spanish. For the follow-up surveys, the research team will contact participants via their preferred method (text or email) and send a link to the follow-up survey. If unsuccessful, the research team will then contact participants by phone to complete the survey via text or call.
Once mammogram results are available, patients will be randomized 1:1 to either usual care or usual care with chatbot, with randomization in permuted blocks of size and stratified by age (\<55 vs. ≥55 years, a proxy for menopause and indicator of risk); rural/frontier vs. urban; language preference (English vs. Spanish); and cohort (normal vs. abnormal result).
This study will randomly invite participants from four groups for focus group discussions (FGDs) based on their mammogram results and adherence to screening recommendations. This study aim to conduct 8 FGDs (2 per group, one in Spanish and one in English) with 8-10 participants each.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Usual Care: This will include participants randomized to usual care.
Chatbot: This will include participants randomized to usual care with the Chatbot.
Other: Chatbot
The Chatbot used in this study will be used after mammography to facilitate follow-up, answer patient questions, and provide information.
Screening Adherence
This outcome measure will test the addition of virtual navigation to usual processes of care to increase screening adherence for underserved women undergoing mobile mammography who have an abnormal breast cancer screening exam. Screening adherence will be measured as a two-point survey item (Yes/No). This outcome measure will report the proportion of participants who self-reported screening adherence.
Time frame: up to 24 months from initiation of study intervention
Receipt of follow-up testing
This outcome measure will test the addition of virtual navigation to usual processes of care to increase follow-up testing for underserved women undergoing mobile mammography who have an abnormal breast cancer screening exam. Receipt of follow-up testing will be measured as survey items. For subjects who were recommended to have additional breast imaging or a breast biopsy, this will report if they completed the recommendation. This outcome measure will report the proportion of individuals who received all recommended follow-up tests after an initial breast screening indicating additional breast imaging or biopsy.
Time frame: up to 12 months from initiation of study intervention
Receipt of episode completion
This outcome measure will test the addition of virtual navigation to usual processes of care to increase episode completion for underserved women undergoing mobile mammography who have an abnormal breast cancer screening exam. Receipt of episode completion will be measured through a survey. This outcome measure will report the proportion of subjects who complete all recommended follow-up steps after initial breast cancer screening or diagnosis, including imaging, biopsy, specialist appointments, and initiation of treatment if applicable.
Time frame: up to 12 months from initiation of study intervention
Plan to share: No
Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 28 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.